Author
Mark Perelis
Ionis Pharmaceuticals (United States)ORCID 0000-0001-5435-2552Unclaimed ORCID profile · follow to get notified of new preprints
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2019-2025 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 13 mutual co-author links4 papers
Recent·Most cited
- PathologyProceedings of the National Academy of SciencesPeer-reviewed✦ In-depth digest
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis
Ikki Sakuma, Rafael Calais Gaspar, Ali R. Nasiri…·Gerald I. Shulman
Cholesterol accumulation in hepatic lipid droplets drives inflammation and fibrosis in mouse and human MASH and is reversed by inhibiting cholesterol synthesis or knocking down Coasy or Hsd17b13.
- Cancer BiologybioRxivPreprint
Integrative CRISPR Screens and RNA-Omics Discover an Essential Role for PUF60-3' Splice Site Interactions in Cancer Progression
Alexandra T. Tankka, Jaclyn M. Einstein, Catherine J. Zhou…·Gene Wei-Ming Yeo
The paper identifies PUF60's role in cancer progression by combining CRISPR screens and RNA-omics, showing its splicing activity supports TNBC proliferation and is a potential therapeutic target.
1 citation - Molecular BiologyCurrent BiologyPeer-reviewed
Cryptochromes-mediated Inhibition of the CRL4Cop1-Complex Assembly Defines an Evolutionary Conserved Signaling Mechanism
Luca Rizzini, Daniel C. Levine, Mark Perelis…·Michele Pagano
The paper shows mammalian Cryptochromes inhibit CRL4Cop1 complex assembly, similar to their function in plants, by interacting with Det1 to repress GR transcription.